Edwards Lifesciences Corporation EW

EW Company Overview

Edwards Lifesciences Corporation (NYSE: EW) is a U.S.-based medical technology company focused on structural heart disease and critical care monitoring technologies. The company develops and manufactures devices used primarily in transcatheter and surgical heart valve replacement, hemodynamic monitoring, and advanced patient monitoring systems. Edwards operates within the broader cardiovascular medical devices industry and derives the majority of its revenue from products used in the treatment of aortic and mitral valve disease, particularly minimally invasive transcatheter therapies.

The company’s primary business lines include transcatheter aortic valve replacement (TAVR), surgical structural heart products, and critical care technologies. Its flagship product family, the SAPIEN transcatheter heart valve platform, has been a major revenue driver and positioned Edwards as a leading participant in the global TAVR market. Edwards serves hospitals, cardiac surgeons, interventional cardiologists, and intensive care clinicians across developed and emerging healthcare markets. The company traces its roots to the 1958 founding of American Edwards Laboratories and became an independent public company in 2000 following its spin-off from Baxter International. Over time, Edwards evolved from a broader cardiovascular device manufacturer into a company centered on structural heart innovation and minimally invasive cardiac therapies.